Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;149(14):13451-13458.
doi: 10.1007/s00432-023-05152-9. Epub 2023 Jul 18.

Advances in bio-immunotherapy for castration-resistant prostate cancer

Canling Lin  1 , Yonghui Chen  1 , Liji Shi  1 , Huarong Lin  2 , Hongmei Xia  3 , Weihua Yin  4
Affiliations
Review

Advances in bio-immunotherapy for castration-resistant prostate cancer

Canling Lin et al. J Cancer Res Clin Oncol. 2023 Nov.

Abstract

Prostate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change, the disease can progress to castrate-resistant prostate cancer. Because of the poor efficacy of traditional surgery, endocrine therapy, radiation therapy, and chemotherapy, the treatment options for castrate-resistant prostate cancer are limited. Advanced prostate cancer can progress on immunotherapy, and thus, bio -immunotherapy targeting the unique, prostate microenvironment is an important option. In this paper, we systematically revealed the role of three types of bio-immunotherapies (immune checkpoint inhibitors, tumors, vaccines, cytokines) in castrate-resistant prostate cancer, providing a reference for clinical treatment of prostate cancer.

Keywords: Cancer vaccine; Cytokines; Immune checkpoint inhibitors; Immunotherapy; Prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors all declared no conflicts of interest.

Figures

Figure1
Figure1
Prostate cancer vaccine clinical trial
See this image and copyright information in PMC

References

    1. Alabi BR, Liu S, Stoyanova T (2022) Current and emerging therapies for neuroendocrine prostate cancer. Pharmacol Ther 238:108255 - PubMed
    1. Ardiani A, Farsaci B, Rogers CJ et al (2013) Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 19(22):6205–6218 - PMC - PubMed
    1. Baeuerle PA, Kufer P, Bargou R (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11(1):22–30 - PubMed
    1. Barqawi AB, Rodrigues Pessoa R, Crawford ED et al (2021) Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial. Prostate Cancer Prostatic Dis 24(3):750–757 - PubMed
    1. Bonnefoy N, Olive D, Vanhove B (2019) Next generation of anti-immune checkpoints antibodies. Med Sci (paris) 35(12):966–974 - PubMed

LinkOut - more resources